Publication:
Expert panel on cost analysis of atrial fibrillation

Simple item page
dc.contributor.authorFAK, ALİ SERDAR
dc.contributor.authorsFak, Ali Serdar; Kucukoglu, M. Serdar; Fak, Nazire Afsar; Demir, Mesut; Agir, Aysen A.; Demirtas, Mustafa; Kose, Sedat; Ozdemir, Murat
dc.date.accessioned2022-03-13T12:44:25Z
dc.date.available2022-03-13T12:44:25Z
dc.date.issued2013
dc.description.abstractObjective: To estimate total cost of atrial fibrillation (AF) management concerning acute coronary syndrome, heart failure, stroke and drug related adverse events with respect to clinical practice and available guidelines. Methods: This cost analysis study was based on identification of total costs related to management of acute coronary syndrome, heart failure, stroke and the drug related adverse events in patients with AF based on standardized questionnaire forms filled by experts according to their daily clinical practice and also to ACCF/AHA/ESC guidelines. Total cost included cost items related to treatment, healthcare resources utilization, and diagnostic test and consultations. Results: The yearly cost of acute coronary syndrome per patient was 5.478.43 TL according to expert's view reflecting real clinical practice whereas it was 11.319.44 TL when calculation was based on recommendations in the guidelines. The average total cost of heart failure was 4.523.74 TL according to expert's view whereas it was 2.925.86 TL based on guidelines. The average total cost of stroke was 5.719.25 TL according to expert's view but 7.931.18 TL based on guidelines. Among drug related adverse events, only those related to cardiac adverse events were estimated to be higher according to expert view as compared to guideline recommendations (288.65 vs. 150.99 TL). Conclusions: Reflecting the treatment algorithms in the management of AF and related adverse events, our findings seem to emphasize the extra burden on health economics posed by patients suffering from the uncontrolled disease. (Anadolu Kardiyol Derg 2013; 13: 26-38)
dc.identifier.doi10.5152/akd.2013.004
dc.identifier.eissn2149-2271
dc.identifier.issn2149-2263
dc.identifier.pubmed23070633
dc.identifier.urihttps://hdl.handle.net/11424/237518
dc.identifier.wosWOS:000317361900005
dc.language.isoeng
dc.publisherTURKISH SOC CARDIOLOGY
dc.relation.ispartofANATOLIAN JOURNAL OF CARDIOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAtrial fibrillation
dc.subjectacute coronary syndrome
dc.subjectheart failure
dc.subjectstroke
dc.subjectadverse events
dc.subjectcost analysis
dc.subjectASSOCIATION TASK-FORCE
dc.subjectELEVATION MYOCARDIAL-INFARCTION
dc.subjectGUIDELINES WRITING COMMITTEE
dc.subjectKEY DATA ELEMENTS
dc.subjectQUALITY-OF-LIFE
dc.subjectAMERICAN-COLLEGE
dc.subjectEUROPEAN-SOCIETY
dc.subjectCARDIOVASCULAR ANGIOGRAPHY
dc.subjectPULMONARY REHABILITATION
dc.subjectCARDIOLOGY COMMITTEE
dc.titleExpert panel on cost analysis of atrial fibrillation
dc.typearticle
dspace.entity.typePublication
local.avesis.id258e6a69-0d7c-4119-a918-eb7f7e78f6f3
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.indexed.atTRDIZIN
local.journal.numberofpages13
oaire.citation.endPage38
oaire.citation.issue1
oaire.citation.startPage26
oaire.citation.titleANATOLIAN JOURNAL OF CARDIOLOGY
oaire.citation.volume13
relation.isAuthorOfPublication7fadb6bf-c4a2-4220-9c4e-367d520e3c98
relation.isAuthorOfPublication.latestForDiscovery7fadb6bf-c4a2-4220-9c4e-367d520e3c98

Files

Collections

Research Outputs